NASDAQ:IMMUImmunomedics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Immunomedics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $39.96 -1.36 (-3.29 %) (As of 07/13/2020 04:00 PM ET) Add Compare Share Today's Range$39.67Now: $39.96▼$42.4750-Day Range$30.18MA: $34.49▼$42.3052-Week Range$8.80Now: $39.96▼$42.94Volume141,017 shsAverage Volume4.36 million shsMarket Capitalization$9.23 billionP/E RatioN/ADividend YieldN/ABeta3.36 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140, a humanized antibody directed against an immune response target. Its other product candidates include products for the treatment of cancer and autoimmune diseases, including epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune, to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with The Bayer Group for the development of epratuzumab; clinical and preclinical collaborations with academic cancer institutions, identifying new cancer indications for sacituzumab govitecan and the biology of the Trop-2 antigen; and research collaboration with the Memorial Sloan Kettering Cancer Center to investigate Sacituzumab Govitecan and Labetuzumab Govitecan in preclinical cancer models. Immunomedics, Inc. has a partnership agreement with the Samsung BioLogics Co., Ltd. to manufacture hRS7, an Immunomedics proprietary humanized antibody. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.Read More Beat the Market (BTM) Rank™ 2.4 Analyst's Opinion Consensus RatingImmunomedics has received a consensus rating of Buy. The company's average rating score is 2.85, and is based on 11 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $37.38, Immunomedics has a potential downside of 6.4% from its current price of $39.96.Amount of Analyst CoverageImmunomedics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.4 Community Rank Outperform VotesImmunomedics has received 436 “outperform” votes. (Add your “outperform” vote.)Underperform VotesImmunomedics has received 461 “underperform” votes. (Add your “underperform” vote.)Community SentimentImmunomedics has received 51.39% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Immunomedics and other stocks. Vote “Outperform” if you believe IMMU will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IMMU will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldImmunomedics does not currently pay a dividend.Dividend GrowthImmunomedics does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immunomedics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $49,875,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 9.40% of the stock of Immunomedics is held by insiders.Percentage Held by Institutions76.58% of the stock of Immunomedics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Immunomedics are expected to grow in the coming year, from ($1.45) to ($0.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunomedics is -21.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunomedics is -21.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunomedics has a P/B Ratio of 28.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.89 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:IMMU Previous Symbol CUSIP45290710 CIK722830 Webwww.immunomedics.com Phone973-605-8200Debt Debt-to-Equity Ratio0.05 Current Ratio8.37 Quick Ratio8.37Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$290,000.00 Price / Sales31,816.43 Cash FlowN/A Price / Cash FlowN/A Book Value$1.38 per share Price / Book28.96Profitability EPS (Most Recent Fiscal Year)($1.84) Net Income$-357,190,000.00 Net MarginsN/A Return on Equity-246.01% Return on Assets-67.35%Miscellaneous Employees346 Outstanding Shares230,900,000Market Cap$9.23 billion Next Earnings DateN/A OptionableOptionable NASDAQ:IMMU Rates by TradingView Receive IMMU News and Ratings via Email Sign-up to receive the latest news and ratings for IMMU and its competitors with MarketBeat's FREE daily newsletter. Immunomedics (NASDAQ:IMMU) Frequently Asked Questions How has Immunomedics' stock been impacted by COVID-19 (Coronavirus)? Immunomedics' stock was trading at $13.38 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, IMMU shares have increased by 198.7% and is now trading at $39.96. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Immunomedics? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunomedics in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Immunomedics. How were Immunomedics' earnings last quarter? Immunomedics, Inc. (NASDAQ:IMMU) issued its quarterly earnings data on Wednesday, May, 6th. The biopharmaceutical company reported ($0.44) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.46) by $0.02. During the same quarter in the previous year, the company posted ($0.46) EPS. View Immunomedics' earnings history. What price target have analysts set for IMMU? 13 brokers have issued 12 month target prices for Immunomedics' stock. Their forecasts range from $22.00 to $56.00. On average, they expect Immunomedics' share price to reach $37.38 in the next year. This suggests that the stock has a possible downside of 6.4%. View analysts' price targets for Immunomedics. What are Wall Street analysts saying about Immunomedics stock? Here are some recent quotes from research analysts about Immunomedics stock: 1. According to Zacks Investment Research, "Immunomedics reported a narrower-than-expected loss in the first quarter. The company got a significant boost with the recent FDA approval for its lead drug, Trodelvy, an antibody-drug conjugate (ADC), for the treatment of patients with mTNBC. The commercial launch of the drug is underway. The successful commercialization of the drug will bring in sales for the company. Meanwhile, Trodelvy is being evaluated in several label expansion studies, including earlier-line settings for breast cancer and other cancer indications. A late-stage study on the candidate was recently halted due to its compelling efficacy. Immunomedics is also evaluating acituzumab in other cancer types. A potential label expansion of the drug will further boost growth prospects. However, competition is stiff from bigwigs in the market. Pipeline setbacks will also weigh on shares." (6/30/2020) 2. HC Wainwright analysts commented, "We remind investors that sacituzumab previously achieved a 31% 6.8-month median progression-free survival (mPFS) which, in our view, compares favorably to chemotherapy’s effect in this patient population (10-13% ORR and 3-4 month mPFS). Accordingly, we reiterate our Buy rating, while reducing our 12-month price target from $28 to $26 to account for the removal of the second- line HR+, HER2- mBC setting from our assumptions. IMMU-132 filing resubmission remains on track for early 4Q19." (8/8/2019) Has Immunomedics been receiving favorable news coverage? News stories about IMMU stock have trended very negative on Monday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Immunomedics earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about Immunomedics. Who are some of Immunomedics' key competitors? Some companies that are related to Immunomedics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). View all competitors. What other stocks do shareholders of Immunomedics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immunomedics investors own include Celgene (CELG), Seattle Genetics (SGEN), Synergy Pharmaceuticals (SGYP), NVIDIA (NVDA), Micron Technology (MU), ImmunoGen (IMGN), Gilead Sciences (GILD), Netflix (NFLX), Novavax (NVAX) and Advanced Micro Devices (AMD). Who are Immunomedics' key executives? Immunomedics' management team includes the following people: Dr. Behzad Aghazadeh Ph.D., Exec. Chairman (Age 48)Dr. Morris Z. Rosenberg, Chief Technology Officer (Age 59)Mr. Scott A. Canute MBA, Exec. Director (Age 58)Mr. Brendan Delaney, Chief Commercial Officer (Age 44)Dr. Robert Iannone, Chief Medical Officer and Head of R&D (Age 52) What is Immunomedics' stock symbol? Immunomedics trades on the NASDAQ under the ticker symbol "IMMU." Who are Immunomedics' major shareholders? Immunomedics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.03%), FNY Investment Advisers LLC (0.01%) and Fulton Bank N. A. (0.00%). Company insiders that own Immunomedics stock include Avoro Capital Advisors Llc and Bryan Ball. View institutional ownership trends for Immunomedics. Which major investors are buying Immunomedics stock? IMMU stock was purchased by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC, Fulton Bank N. A., and Envestnet Asset Management Inc.. Company insiders that have bought Immunomedics stock in the last two years include Avoro Capital Advisors Llc, and Bryan Ball. View insider buying and selling activity for Immunomedics. How do I buy shares of Immunomedics? Shares of IMMU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Immunomedics' stock price today? One share of IMMU stock can currently be purchased for approximately $39.96. How big of a company is Immunomedics? Immunomedics has a market capitalization of $9.23 billion and generates $290,000.00 in revenue each year. The biopharmaceutical company earns $-357,190,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. Immunomedics employs 346 workers across the globe. What is Immunomedics' official website? The official website for Immunomedics is www.immunomedics.com. How can I contact Immunomedics? Immunomedics' mailing address is 300 AMERICAN RD, MORRIS PLAINS NJ, 07950. The biopharmaceutical company can be reached via phone at 973-605-8200 or via email at [email protected] This page was last updated on 7/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
